Wednesday Feb 26
Catabasis Pharmaceuticals, Inc. Names Vice President Of Research
Dr. Nichols brings to Catabasis 25 years of drug development experience, leading efforts from target discovery through translational research and early clinical development for pharmaceutical and biotechnology companies.
New firm Voyager to use viruses to attack diseases
A Cambridge biotechnology company launched Wednesday is taking aim at Parkinson's disease and ALS with a new gene therapy that deliberately infects patients with a virus.
Eleven Bio becomes 3rd local biotech to go public, with $50M offering
With plans to start trading publicly today, Eleven Biotherapeutics lowered its initially-proposed offering of about $69 million to raise a more modest $50 million to fund trials of its potential drug to treat dry eye disease.
Ambrx, Inc. Appoints To Board Of Directors
Mr. Greene has more than 20 years of experience in the healthcare, pharmaceutical and biotechnology industries.
Catabasis Pharmaceuticals, Inc. Announces Appointment Of As Independent Director
Mr. Bate is an experienced biotechnology executive having led companies at various stages of development.